| abstract |
The present invention is based on the discovery that certain fermentation products of marine actinomycetes CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 strain and the CNB476 strain are within the scope of the Micromonosporaceae family, and the common alias Salinospora is regarded as this obligate marine group. The reaction product produced by this strain is classified as salinosporamide, a neoplastic disorder due to its low molecular weight, low IC 50 value, high pharmaceutical potency, and selectivity for cancer cells over fungi Is particularly advantageous for treating |